Other Information
−Removed: Preliminary Unaudited Cash and Cash Equivalents as of March 31, 2021 and Net Loss for the Three Month Period Ended March 31, 2021.
−Removed: On May 10, 2021, we announced that although we had not finalized our full financial results for the fiscal quarter ended March 31, 2021, we expected to report that we had (a) cash, cash equivalents, restricted cash and marketable securities of approximately $27.3 million as of March 31, 2021 and (b) a net loss of approximately $8.4 million for the three-month period ended March 31, 2021.
−Removed: The estimated cash, cash equivalents, restricted cash and marketable securities and net loss figures were preliminary and unaudited, and represented our management’s estimates as of May 10, 2021.
−Removed: The financial information was subject to the completion of our financial closing procedures with respect to the interim consolidated financial statements, as of and for the three-month period ended March 31, 2021, which are included elsewhere in this Quarterly Report on Form 10-Q.
+Added: Not applicable.
The following exhibits are incorporated by reference or filed as part of this report.
−Removed: 2.1 Agreement and Plan of Merger, dated as of March 29, 2021, by and among Millendo Therapeutics, Inc., Mars Merger Corp.
−Removed: and Tempest Therapeutics, Inc.
−Removed: (incorporated by reference from Exhibit 2.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2021, File No.
−Removed: 3.1 Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference from Exhibit 3.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2019 File No.
−Removed: 3.2 Third Amended and Restated Bylaws, as Amended, of the Registrant (incorporated by reference from Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 9, 2018 File No.
−Removed: 10.1^ Executive Chair Agreement, by and between Millendo Therapeutics US, Inc.
−Removed: Owens, Ph.D., dated January 27, 2021 (incorporated by reference from Exhibit 10.29 to the Annual Report on Form 10-K, filed on March 29, 2021, File No.
−Removed: 10.2^ Separation from Employment, by and between Millendo Therapeutics US, Inc.
−Removed: Owens, Ph.D., dated January 27, 2021 (incorporated by reference from Exhibit 10.30 to the Annual Report on Form 10-K, filed on March 29, 2021, File No.
−Removed: 10.3^ Amended and Restated Employment Agreement between Louis Arcudi III and Millendo Therapeutics US, Inc., dated as of January 27, 2021 (incorporated by reference from Exhibit 10.31 to the Annual Report on Form 10-K, filed on March 29, 2021, File No.
−Removed: 10.4^ Amended and Restated Employment Agreement between Jennifer Minai-Azary and Millendo Therapeutics US, Inc., dated of January 27, 2021 (incorporated by reference from Exhibit 10.32 to the Annual Report on Form 10-K, filed on March 29, 2021, File No.
−Removed: 31.1* Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002
−Removed: 31.2* Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002
−Removed: Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) pursuant to Section 906 of Sarbanes-Oxley Act of 2002
−Removed: 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
−Removed: 101.SCH Inline XBRL Taxonomy Extension Schema Document
−Removed: 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
−Removed: 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
−Removed: 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: 104 Cover Page Interactive Data File - the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments.
−Removed: ______________________________________________________
−Removed: * Filed herewith.
−Removed: ^ Indicates management contract or compensatory plan.
−Removed: + This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
−Removed: Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
+Added: Incorporation by Reference
+Added: Description of Exhibit
+Added: Restated Certificate of Incorporation of the Registrant, as amended
+Added: Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 24, 2021
+Added: June 28, 2021
+Added: Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 25, 2021
+Added: June 28, 2021
+Added: Third Amended and Restated Bylaws of the Registrant
+Added: August 9, 2018
+Added: Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Executive Officer and Financial Officer pursuant to 18 U.S.C.
+Added: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
+Added: XBRL Taxonomy Extension Schema Document.
+Added: XBRL Taxonomy Extension Calculation Linkbase Document.
+Added: XBRL Taxonomy Extension Definition Linkbase Document.
+Added: XBRL Taxonomy Extension Label Linkbase Document.
+Added: XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)
+Added: The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q
+Added: and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: MILLENDO THERAPEUTICS, INC.
−Removed: /s/ Louis Arcudi III
−Removed: Louis Arcudi III
−Removed: President and Chief Executive Officer (Principal Executive Officer)
−Removed: /s/ Jennifer Minai-Azary
−Removed: Jennifer Minai-Azary
−Removed: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer
+Added: TEMPEST THERAPEUTICS, INC.
+Added: /s/ Stephen Brady
+Added: Stephen Brady
+Added: Chief Executive Officer (Principal Executive Officer)
+Added: /s/ Nicholas Maestas
+Added: Nicholas Maestas
+Added: Vice-President, Strategy and Finance (Principal Financial Officer)
+Added: August 12, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.